Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11354278 | 0.93 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL24856 | 0.62 | — | — | |
| SCHEMBL35239 | 0.62 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL432519 | 0.62 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL31512472 | 0.62 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL1160768 | 0.60 | — | — | |
| SCHEMBL15400759 | 0.60 | ALDH1A1 (0.40) | ALDH1A1 | |
| Water SCHEMBL20597605 | 0.60 | ALDH1A1 (0.40) | ALDH1A1 | |
| Phosphine SCHEMBL21380516 | 0.60 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL10703282 | 0.60 | ALDH1A1 (0.40) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5880295-A | Process for the preparation of diamine intermediates useful in the synthesis of HIV protease inhibitors | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-03-09 | — | — | US | claimed |
| EP-1558603-B1 | OXYGE-CONTAINING HETEROCYCLIC FUSED NAPHTHOPYRANS | INSIGHT EQUITY A P X LP (US) | 2015-07-22 | — | — | EP | disclosed |
| EP-2578589-A1 | Oxygen-containing heterocyclic fused naphthopyrans having photochromic properties | Insight Equity A.P.X., LP (US) | 2013-04-10 | — | — | EP | disclosed |
| EP-1558603-A4 | OXYGE-CONTAINING HETEROCYCLIC FUSED NAPHTHOPYRANS | INSIGHT EQUITY A P X LP (US) | 2009-03-18 | — | — | EP | disclosed |
| US-7074943-B2 | Oxygen-containing heterocyclic fused naphthopyrans | VISION-EASE LENS (US) | 2006-07-11 | — | — | US | disclosed |
| US-20060030673-A1 | Oxygen-containing heterocyclic fused naphthopyrans | HOYA OPTICAL LABS OF AMERICA, INC. | 2006-02-09 | — | — | US | disclosed |
| US-6963003-B2 | Oxygen-containing heterocyclic fused naphthopyrans | VISION-EASE LANE (US) | 2005-11-08 | — | — | US | disclosed |
| EP-1558603-A2 | OXYGE-CONTAINING HETEROCYCLIC FUSED NAPHTHOPYRANS | Vision-Ease Lens, Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040215024-A1 | Oxygen-containing heterocyclic fused naphthopyrans | VISION-EASE LENS, INC. | 2004-10-28 | — | — | US | disclosed |
| WO-2004047674-A2 | OXYGE-CONTAINING HETEROCYCLIC FUSED NAPHTHOPYRANS | VISION-EASE LENS, INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| US-6608215-B2 | Photochromic ophthalmic or sun protection lenses, glass paneling | VISION-EASE LENS, INC. | 2003-08-19 | — | — | US | disclosed |
| US-20030092918-A1 | Oxygen-containing heterocyclic fused naphthopyrans | VISION-EASE LENS, INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2003025638-A1 | OXYGEN-CONTAINING HETEROCYCLIC FUSED NAPHTHOPYRANS | VISION-EASE LENS, INC. (US) | 2003-03-27 | — | — | WO | disclosed |
| US-5880295-A | Process for the preparation of diamine intermediates useful in the synthesis of HIV protease inhibitors | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-03-09 | — | — | US | disclosed |
| US-5559252-A | Process for the preparation of diamine intermediates useful in the synthesis of HIV protease inhibitors | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-09-24 | — | — | US | disclosed |
| US-4155918-A | Novel D-homosteroids | HOFFMANN-LA ROCHE INC. (US) | 1979-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092918-A1 | Oxygen-containing heterocyclic fused naphthopyrans | NQO1, NFE2L2, NDUFV2 | ALDH1A1 202/4885 |
| US-20060030673-A1 | Oxygen-containing heterocyclic fused naphthopyrans | NQO1, NFE2L2, NDUFV2 | ALDH1A1 176/4885 |
| US-20040215024-A1 | Oxygen-containing heterocyclic fused naphthopyrans | NQO1, NFE2L2, NDUFV2 | ALDH1A1 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.